Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy

Nature Reviews Clinical Oncology

Volumn 12, Issue 6, 2015, Pages 335-343

  King, Tari A ^a   Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FALSE NEGATIVE RESULT; HIGH RISK PATIENT; HUMAN; MASTECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; LABORATORY DIAGNOSIS; LYMPH NODE METASTASIS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PARTIAL MASTECTOMY; PREOPERATIVE CARE; PROCEDURES;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PATIENT SELECTION; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY;

EID: 84930178499     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.63     Document Type: Review

References (68)

1. Bozzetti, F., Saccozzi, R., De Lena, M. & Salvadori, B. Inflammatory cancer of the breast: analysis of 114 cases. J. Surg. Oncol. 18, 355-361 (1981).
2. Haagensen, C. D. & Stout, A. P. Carcinoma of the breast. III. Results of treatment, 1935-1942. Ann. Surg. 134, 151-172 (1951).
3. Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405-410 (1976).
4. Fisher, B. et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N. Engl. J. Med. 292, 117-122 (1975).
5. Buzdar, A.U., Montague, E. D., Barker, J. L., Hortobagyi, G. N. & Blumenschein, G. R. Management of inflammatory carcinoma of breast with combined modality approach-An update. Cancer 47, 2537-2542 (1981).
6. De Lena, M., Zucali, R., Viganotti, G., Valagussa, P. & Bonadonna, G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother. Pharmacol. 1, 53-59 (1978) .
7. Hortobagyi, G. N. et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62, 2507-2516 (1988).
8. Mauri, D., Pavlidis, N. & Ioannidis, J. P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-Analysis. J. Natl Cancer Inst. 97, 188-194 (2005).
9. Mieog, J. S., van der Hage, J. A. & van de Velde, C. J. Neoadjuvant chemotherapy for operable breast cancer. Br. J. Surg. 94, 1189-1200 (2007).
10. Fisher, B. et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15, 2483-2493 (1997).
11. Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164-172 (2014).
12. Prowell, T. M. & Pazdur, R. Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 366, 2438-2441 (2012).
13. van der Hage, J. A. et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol. 19, 4224-4237 (2001).
14. Bear, H. D. et a l. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 21, 4165-4174 (2003).
15. Baselga, J. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
16. Guarneri, V. et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J. Clin. Oncol. 30, 1989-1995 (2012).
17. Untch, M. et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13, 135-144 (2012).
18. Katz, S. J. et al. Patient involvement in surgery treatment decisions for breast cancer. J. Clin. Oncol. 23, 5526-5533 (2005).
19. Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
20. Gianni, L. et al. Gene expression p rofiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23, 7265-7277 (2005).
21. Petrelli, F. & Barni, S. Response t o neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-Analysis of published trials including 1,764 lobular breast cancer. Breast Cancer Res. Treat. 142, 227-235 (2013).
22. Li ps, E. H. et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res. Treat 136, 35-43 (2012).
23. Ataseven, B. et al. Impact of multif ocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann. Surg. Oncol. 22, 1118-1127 (2015).
24. Boughey, J. C. et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective mul ticenter clinical trial. Ann. Surg. 260, 608-614 (2014).
25. Hylton, N. M. et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 263, 663-672 (2012).
26. Marinovich, M. L. et al. Meta-Analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J. Natl Cancer Inst. 105, 321-333 (2013).
27. Rosen, E. L. et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am. J. Roentgenol. 181, 1275-1282 (2003).
28. Turnbull, L. W. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed. 22, 28-39 (2009).
29. Yeh, E. et al. Prospective comp arison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am. J. Roentgenol. 184, 868-877 (2005).
30. Chen, J. H. et al. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology 261, 735-743 (2011).
31. De Los Santos, J. F. et al. Magnetic resonance imaging as a predictor of pathologic response i n patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 119, 1776-1783 (2013).
32. Straver, M. E. et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann. Surg. 251, 701-707 (2010).
33. Charehbili, A. et al. Accuracy of MRI for treatment response assessment after taxane-And anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer. Eur. J. Surg. Oncol. 40, 1216-1221 (2014).
34. Weiss A.,et al Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy. Ann. Surg. Oncol. 21, 3310-3316, 2014).
35. Boughey , J. C. et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann. Surg. 244, 464-470 (2006).
36. Wolmark, N., Wang, J., Mamounas, E., Bryant, J. & Fisher, B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Na tl Cancer Inst. Monogr. 2001, 96-102 (2001).
37. Chen, A. M. et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J. Clin. Oncol. 22, 2303-2312 (2004).
38. Abt, N. B. et al. Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg. 149, 1068-1076 (2014).
39. Gradishar, W. J. et al. Breast cancer version 3.2014. J. Natl Compr. Canc. Netw. 12, 542-590 (2014).
40. Mamounas, E. P. et al. Sentinel node biopsy after neoadjuvant chemo therapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 23, 2694-2702 (2005).
41. Hunt, K. K. et al. Sentinel lymph node surgery after neoadju vant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann. Surg. 250, 558-566 (2009).
42. van Deurzen, C. H. et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur. J. Cancer 45, 3124-3130 (2009).
43. Xing, Y. et al. Meta-Analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg. 93, 539-546 (2006).
44. Classe, J. M. et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J. Clin. Oncol. 27, 726-732 (2009).
45. Goyal, A., Newcombe, R. G., Chhabra, A. & Mansel, R. E. Factors affecting failed local isation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase. Breast Cancer Res. Treat. 99, 203-208 (2006).
46. Kelly, A. M., Dwamena, B., Cronin, P. & Carlos, R. C. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad. Radiol. 16, 551-563 (2009).
47. Kim, T., Giuliano, A. E. & Lyman, G. H. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106, 4-16 (2006).
48. McMasters, K. M. et al. Sentinel lymph node b iopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J. Clin. Oncol. 18, 2560-2566 (2000).
49. Tafra, L., Verbanac, K. M. & Lannin, D. R. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am. J. Surg. 182, 312-315 (2001).
50. Veronesi, U. et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349, 546-553 (2003).
51. Mamounas, E. P. et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J. Clin. Oncol. 30, 3960-3966 (2012).
52. Dominici, L. S. et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116, 2 884-2889 (2010).
53. Hennessy, B. T. et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J. Clin. Oncol. 23, 9304-9311 (2005).
54. Shen, J. et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109, 1255-1263 (2007).
55. Alvarado R.,et al The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann. Surg. Oncol. 19, 3177-3184, 2012).
56. Boileau, J. F. et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J. Clin. Oncol. 33, 258-264 (2015).
57. Boughey, J. C. et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310, 1455-1461 (2013).
58. Kuehn, T. et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 14, 609-618 (2013).
59. Krag, D. N. et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8, 881-888 (2007).
60. Tafra, L. et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann. Surg. 233, 51-59 (2001).
61. Donker, M. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, ph ase 3 non-inferiority trial. Lancet Oncol. 15, 1303-1310 (2014).
62. Giuliano, A. E. et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305, 569-575 (2011).
63. Giuliano, A. E. et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patie nts with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann. Surg. 252, 426-432 (2010).
64. Krag, D. N. et al. Sentinel-lymph-node resection com pared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 11, 927-933 (2010).
65. Edge, S. et al. AJCC cancer staging manual 7th edn (Springer, 2010).
66. Boughey, J. C. et al. Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy-Results from a prospectiv e trial-ACOSOG Z1071 (Alliance) [Poster No. P2-01-02]. Presented at the 2014 San Antonio Breast Cancer Symposium.
67. NCI Community Oncology Research Program. CTSU Alliance A011202: A Randomized Phase III Trial Evaluating the Role o f Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy [online]. http://www.kccop.org/cancer-trials/breast/index.cgi/summary?tID=110 (2014).
68. Mamounas, E. P. et al. NSABP B-51/RTOG 1304: randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC [abstract]. J. Clin. Oncol. 32, TPS1141 (2014).